Mark Bamforth is the founder and President & CEO of Arranta Bio, which was established in May 2019.
In 2015, Mr. Bamforth founded Brammer Bio, a viral vector CDMO supporting cell and gene therapy companies, which grew from 100 to 600 employees, with a team in Florida producing early clinical materials and two commercial manufacturing sites in Massachusetts. Brammer Bio was acquired by Thermo Fisher Scientific in April 2019.
In 2010, Mr. Bamforth founded Gallus BioPharmaceuticals, a CDMO supplying biopharmaceuticals, with the acquisition of a commercial facility in St. Louis from Janssen. Including the subsequent acquisition of Laureate Biopharma in Princeton, NJ, the experienced team expanded from 160 to over 400. In September 2014, Gallus was sold to DPx Holdings B.V., which later became part of Thermo Fisher Scientific.
Prior to this, Mr. Bamforth gained 22 years of experience in the UK and USA at Genzyme Corp, including running a diverse global manufacturing operation and pharmaceutical CMO business. He began his career as a petroleum engineer in the UK exploration for North Sea oil, then became a chemical engineer in the Scottish whisky industry.
Mr. Bamforth serves on the Boards of MassBio, Entrepreneurial Scotland, the Wentworth Institute of Technology, Continuus Pharmaceuticals and Avid Bioservices. He holds a Bachelor’s Degree in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.